HeartSciences Inc. Files 8-K with Financials and Other Events

TL;DR

HeartSciences filed an 8-K on 9/5/25 covering financials and other events.

AI Summary

HeartSciences Inc. filed an 8-K on September 8, 2025, reporting events as of September 5, 2025. The filing includes information on financial statements and exhibits, and other events. The company, formerly Heart Test Laboratories, Inc., is incorporated in Texas and operates in the orthopedic, prosthetic & surgical appliances & supplies industry.

Why It Matters

This 8-K filing provides an update on the company's financial reporting and other significant events, which is crucial for investors to assess the company's current status and future prospects.

Risk Assessment

Risk Level: low — This filing is a routine 8-K reporting financial statements and other events, not indicating any immediate financial distress or significant operational changes.

Key Numbers

• 001-41422 — Commission File Number (Identifies the company's SEC filing history)
• 26-1344466 — IRS Employer Identification No. (Company's tax identification number)

Key Players & Entities

• HeartSciences Inc. (company) — Registrant
• Heart Test Laboratories, Inc. (company) — Former Company Name
• September 05, 2025 (date) — Date of earliest event reported
• September 8, 2025 (date) — Date of Report
• Texas (location) — State of Incorporation
• 550 Reserve Street, Suite 360 (address) — Principal Executive Offices
• Southlake, Texas 76092 (address) — Principal Executive Offices Location

FAQ

Key Financial Figures

• $3.50 — y (the "Units") at an offering price of $3.50 per Unit, for a maximum offering amount
• $15,000,000 — Unit, for a maximum offering amount of $15,000,000 worth of Units (collectively, the "Offe
• $0.001 — y's Series D Preferred Stock, par value $0.001 per share (the "Series D Preferred Stoc
• $5.00 — common stock"), at an exercise price of $5.00 per share. As of September 5, 2025, t
• $5.4 million — 25, the Company has received a total of $5.4 million of gross proceeds, resulting in the iss
• $1,805,000 — mber 5, 2025, the Company has exchanged $1,805,000 of an unsecured promissory note issued

Filing Documents

• hscs-20250905.htm (8-K) — 51KB
• 0001468492-25-000006.txt ( ) — 188KB
• hscs-20250905.xsd (EX-101.SCH) — 45KB
• hscs-20250905_htm.xml (XML) — 6KB

01 Other Events

Item 8.01 Other Events. Regulation A Offering As previously disclosed, on February 12, 2025, HeartSciences, Inc. (the "Company") filed an Offering Statement on Form 1-A (File No. 024-12572) (as amended and supplemented from time to time, the "Form 1-A"), with the U.S. Securities and Exchange Commission (the "SEC") and which was qualified by the SEC on March 10, 2025, to register the offering of up to 4,285,714 units of the Company (the "Units") at an offering price of $3.50 per Unit, for a maximum offering amount of $15,000,000 worth of Units (collectively, the "Offering"). Each Unit consists of one share of the Company's Series D Preferred Stock, par value $0.001 per share (the "Series D Preferred Stock") and one warrant (each a "Warrant" and collectively the "Warrants") to purchase one share of the Company's common stock, $0.001 par value per share (the "common stock"), at an exercise price of $5.00 per share. As of September 5, 2025, the Company has received a total of $5.4 million of gross proceeds, resulting in the issuance of 1,556,409 Units, as a result of several closings of the Offering. As of September 5, 2025, holders of 1,054,549 shares of Series D Preferred Stock, received as part of the issued Units, have elected to convert such shares of Series D Preferred Stock into 1,054,549 shares of common stock (the "Reg A Issuance"). Debt Exchange As of September 5, 2025, the Company has exchanged $1,805,000 of an unsecured promissory note issued to a certain third party for 506,348 shares of the Company's common stock, reducing the principal amount of such note by such amount (the "Debt Exchange"). As a result of the Reg A Issuance and the Debt Exchange, there are 2,654,540 shares of common stock issued and outstanding as of September 5, 2025.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description Exhibit 104* Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. HEARTSCIENCES INC. Date: September 6, 2025 By: /s/ Andrew Simpson Andrew Simpson President, Chief Executive Officer and Chairman of the Board of Directors

View Full Filing

View this 8-K filing on SEC EDGAR